dayneyus
3 years ago
PhaseII Clinical trail Data locked end June, start of data analysis in late July
We should be hearing results very soon!
TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (βArchβ or the βCompanyβ) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review.
After the recruitment of the last patient into the trial in early May, the Companyβs Phase II data team reconciled the patient data collected from the seven clinical sites that participated in the trial. The database containing the trial data was then locked at the end of June, which enabled the start of data analysis in late July. All of the Phase II clinical sites in Canada, the U.S. and Turkey have been officially closed.
dayneyus
3 years ago
In Phase II of covid19 clinical trails
https//clinicaltrails.gov/ct2/show/ntc04402957
From8K period ending 06/30/21
ARCH BIOPARTNERS INC.
Notes to Condensed Interim Consolidated Financial Statements Nine Months Ended June 30, 2021 and 2020 (Unaudited - See Notice of No Auditor Review)
1. DESCRIPTION OF OPERATIONS
Arch Biopartners Inc. (the βCompanyβ) is a portfolio based biotechnology company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The Company works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
At present, the Company is focused on the clinical development of its lead drug candidate Metablok TM.
β’ Metablok TM - or βLSALT peptideβ, has the potential to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys which often results in organ damage or failure, including in the case of sepsis and COVID-19;
The Company has three additional technology platforms in its portfolio under development:
β’ AB569 - a new drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily in the lungs, and wounds;
β’ Borg: Peptide-Solid Surface Interface - binding of proprietary peptides to solid metal and plastic surfaces to inhibit biofilm formation and reduce corrosion; and
β’ MetaMx TM - proprietary synthetic molecules that target brain tumour initiating cells and invasive glioma cells.
The Company owns, or has exclusive licensing rights on the intellectual property ("IP") emanating from the programs listed above.
The corporate headquarters are located in Toronto, Ontario.